The structural profiles are close, with Medpace carrying a narrow edge on profitability. Neurocrine Biosciences still leads on growth and stability, which keeps the comparison from looking entirely one-sided. In the market, Neurocrine Biosciences carries the stronger setup — intact trend against Medpace's broken trend. That leaves a split case: the structural lead stays with Medpace, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
Most of the separation is still concentrated in profitability.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
The pair sits on a clearly comparable long-term path, though it is not a near-twin match.
The strongest overlap appears in investment intensity and recent revenue growth.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in profitability.
Left means cheaper relative valuation. Higher means stronger structure.
The setup stays mixed because structure and the price setup do not align cleanly in one direction.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where MEDP and NBIX each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Capital efficiency adds support, with a 468-point ROIC advantage.
A meaningful counterforce remains in stability, which keeps the comparison from looking completely one-sided.
The main read on profitability is clearer than the broader score gap.
Break down the MEDP vs NBIX comparison across all dimensions with the full interactive tool.
Explore how MEDP and NBIX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.